# Loredana Puca

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 26 papers | 3,755 citations | 394421 19 h-index | 642732 23 g-index |
| 28 all docs | 28 docs citations | 28 times ranked | 6208 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine, 2016, 22, 298-305. | 30.7 | 1,193 |
| 2 | Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477. | 9.4 | 735 |
| 3 | N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577. | 16.8 | 394 |
| 4 | Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404. | 12.8 | 246 |
| 5 | A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical Cancer Research, 2019, 25, 43-51. | 7.0 | 177 |
| 6 | Emerging Variants of Castration-Resistant Prostate Cancer. Current Oncology Reports, 2017, 19, 32. | 4.0 | 150 |
| 7 | ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278. | 12.8 | 143 |
| 8 | N-Mycâ€“mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. Journal of Clinical Investigation, 2019, 129, 3924-3940. | 8.2 | 115 |
| 9 | Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science Translational Medicine, 2019, 11, . | 12.4 | 105 |
| 10 | Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030593. | 6.2 | 76 |
| 11 | Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549. | 12.8 | 76 |
| 12 | Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, . | 12.6 | 75 |
| 13 | Î±-arrestin 1 (ARRDC1) and Î²-arrestins cooperate to mediate Notch degradation in mammals. Journal of Cell Science, 2013, 126, 4457-4468. | 2.0 | 52 |
| 14 | Î±-Arrestins â€“ new players in Notch and GPCR signaling pathways in mammals. Journal of Cell Science, 2014, 127, 1359-1367. | 2.0 | 50 |
| 15 | SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 1157-1164. | 4.1 | 44 |
| 16 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12. | 3.0 | 24 |
| 17 | Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096. | 21.0 | 24 |
| 18 | An emerging role for cytopathology in precision oncology. Cancer Cytopathology, 2016, 124, 167-173. | 2.4 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. PLoS ONE, 2008, 3, e4070. | 2.5 | 20 |
| 20 | Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377. | 12.8 | 16 |
| 21 | Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).. Journal of Clinical Oncology, 2017, 35, 5029-5029. | 1.6 | 5 |
| 22 | Defining a molecular subclass of treatment resistant prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5004-5004. | 1.6 | 3 |
| 23 | First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer.. Journal of Clinical Oncology, 2019, 37, 260-260. | 1.6 | 3 |
| 24 | Abstract 992: Patient-derived tumor organoids of neuroendocrine prostate cancer. , 2017, , . | | 1 |
| 25 | SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).. Journal of Clinical Oncology, 2019, 37, 5065-5065. | 1.6 | 0 |
| 26 | Extracellular Matrix in Synthetic Hydrogelâ€Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). Advanced Materials, 2022, 34, . | 21.0 | 0 |